BioSpace News Archive

Drug Development

New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced important new data from the Phase 3 CASSINI study on the use of oral anticoagulant XARELTO

December 4, 2018
·
18 min read
Biotech Beach

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

Results Are Expected to Prompt Changes in Practice, Improve Patient Outcomes

December 4, 2018
·
14 min read
Business

IDEAYA Biosciences, Inc. appoints Bao Truong as Vice President, Head of Regulatory Affairs

IDEAYA Biosciences, Inc. announced today the appointment of Bao Truong, as vice president, head of regulatory affairs.

December 4, 2018
·
2 min read
Aurora Cannabis Announces 2018 AGM Voting Results

Aurora Cannabis Inc. today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”), held in Edmonton, Alberta, on November 30, 2018.

December 4, 2018
·
5 min read
BioMidwest

InSitu Biologics: Over $2M in Investments Using Reg A+ Mini-IPO to Advance Non-Opioid Pain Drug Candidate into Clinical Trials

InSitu Biologics, Inc., an emerging biotech company focusing on the development of AnestaGel™, has received over $2 million in investments.

December 4, 2018
·
3 min read
Deals

SQI Diagnostics to Extend Warrant Expiry to December 15, 2020

SQI Diagnostics Inc. today announced that it intends to extend the expiry of 7,630,945 outstanding common share purchase warrants (“the Warrants”) of the Company, which were issued in connection with the Company’s December 2015 private placement financing.

December 4, 2018
·
3 min read
Drug Development

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients

Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)

December 4, 2018
·
14 min read
Business

Puration Anticipates Substantial Sales Acceleration From Projected Hemp-Derived CBD Market Expansion From $591 Million to $22 Billion by 2022

Puration, Inc. today released an update on its end of year sales drive to reach or exceed $1 million in sales for 2018 and to add insight into the 2019 anticipated sales growth.

December 4, 2018
·
3 min read
Business

Aridis Expands Research Agreement with the Cystic Fibrosis Foundation and is Awarded FDA Expedited Program Designations

CF Foundation expands research agreement for AR-501 (for cystic fibrosis) to include additional award amount of up to $4.6 million

December 4, 2018
·
6 min read
SMILE Now Approved for Astigmatism at Vance Thompson Vision

At Vance Thompson Vision, we work tirelessly to expand our field of technology to reduce patient dependence on glasses and contact lenses.

December 4, 2018
·
2 min read